Needham analyst Serge Belanger upgraded Amphastar (AMPH) to Buy from Hold with a $36 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Pharmaceuticals Enters Strategic Licensing Agreement
- Cautious Hold Rating on Amphastar Pharmaceuticals Amid Uncertain Product Approvals and Flat Revenue Growth
- Amphastar price target lowered to $25 from $30 at Piper Sandler
- Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights
- Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c